CARLSBAD, Calif., Dec. 20, 2013 /PRNewswire/ -- Life
Technologies Corporation (NASDAQ: LIFE) today announced that
five new American, five European and two Asia Pacific sites joined the Ion AmpliSeq™
Exome Certified Service Provider program. Within three months of
the program's launch, it's become the world's largest network of
next generation-based sequencing service providers with more than
30 members representing some of the premier institutions in the
industry.
Until now, exome sequencing through a service provider has taken
six to eight weeks and required as much as three micrograms of DNA.
Using the Ion AmpliSeq™ Exome Kit, the Ion Proton™ Sequencer, and
Ion Reporter™ Software, these service providers can sequence two
exomes in a single run – going from DNA to results in two
days. Additionally, Ion AmpliSeq™ Exome Certified Service Providers
require just 50 ng of DNA and offer very competitive prices, making
exome sequencing accessible to any researcher. This program
eliminates the need to batch samples just to make the price of
exome sequencing affordable.
"Leveraging Life Technologies Ion PGM™ and Ion Proton™
next-generation sequencing platforms and an expert technical team,
WuXi AppTec offers customer-focused programs to meet your exacting
clinical research needs, including high-quality exome sequencing,"
said Heather Malicki, Scientific
Director, Virology Technology Development, WuXi AppTec.
"The Ion Proton Sequencer's simple and high-throughput workflow,
from sample preparation to sequencing and data analysis, is ideal
for exome analysis and will allow us to better and more quickly
serve our diverse global client base," said Laurent Farinelli, Ph.D., CEO and co-founder of
Geneva-based FASTERIS
SA.
"The Ampliseq exome represents the next step in bringing
sequencing to all, simplifying the workflow and dramatically
reducing the time required," said Richard
Allcock, Ph.D., Associate Professor at the University of
Western Australia and head of the
Lotterywest State Biomedical Facility. "In doing so, it brings
consistency and scalability, allowing exome sequencing to be
performed economically by all laboratories."
The Ion AmpliSeq™ Exome Certified Service Provider program
welcomes the following American, European and Asia
Pacific institutions:
- Kashi Clinical Laboratories, Portland, Ore.
- RUCDR Infinite Biologics, Piscataway,
N.J.
- WuXi AppTec, Philadelphia,
P.A.
- Molecular Resource Center, Memphis,
Tenn.
- Research and Testing Laboratory, Lubbock, Texas
- FASTERIS SA, Plan-les-Ouates, Switzerland
- Eurofins MWG Operon, Ebersberg, Germany
- NIMGenetics S.L., Madrid,
Spain
- GENOMAX - Plateforme de sequencage, Strasbourg, France
- Cellcall Ltd, Budapest,
Hungary
- Lotterywest State Biomedical Facility, Perth, Australia
- DNA Link, Inc., Seoul, South
Korea
In addition to being faster and more affordable, the Ion
AmpliSeq™ Exome Kit delivers the most uniform sequencing
coverage in the industry*, with up to 98 percent of bases covered
at 10-fold, and up to 95 percent of bases covered at 20-fold, for a
single exome.
Customers can receive their data within hours after a sequencing
run with Ion Reporter™ Software, which provides a list of
mutations, including copy number variation and associated
annotations drawn from dozens of public databases. It also enables
service labs to access their data through the web and rich
filtering tools that help them focus on the most relevant
variants.
"The popularity of the Ion AmpliSeq™ Exome Certified Service
Provider program has grown rapidly, reflecting significant
underlying demand for fast, easy-to-use Ion AmpliSeq™ Exome
sequencing," said Maneesh Jain, vice
president of Marketing and Business Development, Ion Torrent. "The
service provider program model enables customers with research
projects of any size to have access to this ground-breaking
technology."
The Ion AmpliSeq™ Exome Certified Service Provider program is
part of the Ion Certified Service Provider program. To learn more,
visit: lifetechnologies.com/ioncsp.
The Ion AmpliSeq™ Exome Kit, Ion Proton™ Sequencer, and Ion
Reporter Software are For Research Use Only. Not for use in
diagnostic procedures.
*For complete details on the performance of the Ion AmpliSeq™
Exome Kit and Ion Proton™ Sequencer, go to our web page at
lifetechnologies.com/ionexome.
About Life Technologies
Life Technologies Corporation (NASDAQ: LIFE) is a global
biotechnology company that is committed to providing the most
innovative products and services to leading customers in the fields
of scientific research, genetic analysis and applied sciences. With
a presence in more than 180 countries, the company's portfolio of
50,000 end-to-end solutions is secured by more than 5,000 patents
and licenses that span the entire biological spectrum –
scientific exploration, molecular diagnostics,
21st century forensics, regenerative medicine and
agricultural research. Life Technologies has approximately 10,000
employees and had sales of $3.8
billion in 2012.
Life Technologies' Safe Harbor Statement
This press
release includes forward-looking statements about our anticipated
results that involve risks and uncertainties. Some of the
information contained in this press release, including, but not
limited to, statements as to industry trends and Life Technologies'
plans, objectives, expectations and strategy for its business,
contains forward-looking statements that are subject to risks and
uncertainties that could cause actual results or events to differ
materially from those expressed or implied by such forward-looking
statements. Any statements that are not statements of historical
fact are forward-looking statements. When used, the words
"believe," "plan," "intend," "anticipate," "target," "estimate,"
"expect" and the like, and/or future tense or conditional
constructions ("will," "may," "could," "should," etc.), or similar
expressions, identify certain of these forward-looking statements.
Important factors which could cause actual results to differ
materially from those in the forward-looking statements are
detailed in filings made by Life Technologies with the
Securities and Exchange Commission. Life Technologies
undertakes no obligation to update or revise any such
forward-looking statements to reflect subsequent events or
circumstances.
(Logo:
http://photos.prnewswire.com/prnh/20110216/MM49339LOGO)
Life Technologies Contact:
Wes
Conard
415-385-4455
wes.conard@lifetech.com
SOURCE Life Technologies Corporation